Research evidence / Overview of studies for Amitriptylin Abcur
Evidence Base for Persistent Low Mood
This section will summarize the structure of the clinical evaluation for major depressive disorder, primarily based on the available Randomized Controlled Trials (RCTs) and subsequent Meta-analyses that assessed changes in defined symptom scores.
Research exploring how symptoms change over time has relied on a large number of short-term clinical trials. In these studies, adult participants diagnosed with major depressive episodes were evaluated, and researchers monitored outcomes related to functional imbalance, specifically changes in depressive symptom severity using standardized rating scales. Studies reported measurements of changes in symptom scores in the group receiving the study drug compared to the placebo group. Research describes that a difference compared to placebo was observed in some studies that included groups with more severe initial symptoms.
The primary limitation of this research is that most trials focus on short-term treatment, usually lasting less than three months. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes, such as sustained symptom monitoring over many months or years. Additionally, some historical studies used in these analyses were performed before current, rigorous methodological standards were fully in place, meaning the evidence quality varies across studies.
Evidence Base for Chronic Neuropathic Pain
This part will detail the research landscape surrounding the medicine in studies examining various nerve pain conditions, focusing on the types and quality of the clinical trials available, and the primary outcomes (like pain intensity reduction) that were measured by researchers.
Amitriptylin Abcur was studied for in research examining outcomes related to physical discomfort in adults with various nerve pain syndromes, such as pain related to diabetes or shingles (post-herpetic neuralgia). These studies included Randomized Controlled Trials (RCTs), where the main outcomes monitored were patient-reported outcomes describing perceived discomfort, specifically the level of change in pain intensity. Research has explored the medicine in studies examining patient-reported outcomes describing perceived discomfort related to functional limitations, including research examining temporary physiological imbalance in conditions presenting with cycles of stability and flare-ups, like recurrent severe headaches.
Findings from available studies often describe observed patterns related to changes in patient-reported outcomes describing perceived discomfort during the short-term study periods. However, the existing evidence for pain conditions is limited by the characteristics of the research itself. Many studies had modest sample sizes and shorter follow-up durations compared to current standards for pain relief trials. This means that certainty remains low regarding the clinical relevance of the measured outcomes.
Evidence for Specialized Use in Pediatric Nocturnal Enuresis
This heading will describe the specific research context for this childhood application, focusing on the structure and limitations of the historical short-term trials that evaluated the effect on wet nights and the subsequent risk of recurrence.
The use of this medicine in children aged 6 years and older with nocturnal enuresis (bedwetting) was studied for in historical clinical trials. These studies explored short-term symptom changes, monitoring how symptoms evolved in the observed populations by counting the number of wet nights over a defined time interval. Trials reported that the use of the study drug was associated with changes in the number of wet nights per week compared to placebo during the study period.
A significant challenge with this specific application is that much of the research is historical, and the evidence quality varies across studies. Furthermore, studies report high rates of recurrence after the medicine is stopped, indicating that long-term effects are not fully established. Therefore, data for children remain insufficient, particularly regarding sustained outcomes after the study drug is discontinued.
Long-Term Studies and Durability of Effect
This block will summarize what is known and, importantly, what is not known about the sustained outcomes for all conditions, outlining the typical follow-up duration of the core evidence and the availability of data beyond the acute treatment phase.
The majority of pivotal studies across all contexts—low mood, pain, and enuresis—are short-term, focusing on acute changes measured during the study period, typically lasting only a few weeks to three months. This means that long-term effects are not fully established and there is limited information for long-term outcomes.
Research exploring maintenance or durability of effect is less common. Therefore, findings help contextualize how patients reported their experience during the initial phase of evaluation, but they do not fully describe the patterns related to symptom management over extended periods. Follow-up durations were limited, meaning the data available for long-term outcomes remains insufficient to draw broad conclusions about sustained use.
Evidence in Specific Patient Groups
This section will outline what research exists for distinct populations, such as children (beyond enuresis), and older adults, summarizing how these groups were represented in the clinical evaluation and where data may be limited or absent.
Research has explored the medicine's use in older adults with both persistent low mood and chronic pain. Results apply only to the populations studied, but these subgroups are often included in broader trials. However, specific, large-scale studies dedicated solely to evaluating the use and outcomes in older adults are limited, meaning subgroup findings are uncertain.
For children and adolescents, the evidence is largely restricted to the specialized use for nocturnal enuresis. Data for certain groups (like pregnant individuals or those with significant co-existing heart conditions) remain insufficient because these populations were often excluded from the initial clinical trials.
Key Limitations and Areas of Uncertainty
This final section will synthesize the main research gaps identified by regulatory and scientific reviews, describing areas such as the methodological quality of historical studies, the small sample sizes in pain trials, and inconsistencies noted across different research papers.
Evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is the age of much of the core evidence; many foundational studies for persistent low mood and enuresis are historical, and evidence quality varies across studies due to differing methodological standards over time. For chronic pain conditions, sample sizes were modest, and follow-up durations were limited, which can make it challenging to establish high certainty about the findings.
Furthermore, comparative evidence is lacking against the newest classes of medicines, and there is limited information for long-term outcomes across the contexts that were studied. Research provides context but not individual predictions, and studies contribute to the broader evidence landscape but do not determine whether an individual will respond similarly.
Key Studies & References
- Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006 (Regulatory assessment on enuresis studies)
- Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)
